The research focus on SLC6A19 as a potential therapeutic target in diabetes should be for type 2 diabetes for now [17,18], with the possibility of reconsidering it as a target for type 1 diabetes as we learn more. The gene discussed is SLC6A19; the disease is type 2 diabetes mellitus.